Science_TechHealth
News 12 of 19

CDSCO Approves Qdenga Dengue Vaccine for Ages 4-60; Dr. Reddy's to Distribute in Private Market by 2027

Target:UPSC GS-IIIMPSCTeachingSSC GAPrelims HighMains MediumStatic GK Link
18 Sept 2026
~2 min
Source: The Hindu
Key Data:CDSCO approval July 2026Age group 4-60 yearsTwo-dose regimen three months apartAvailability first half of 202711-fold increase in dengue cases over 20 years1 in 14 patients infected with multiple serotypes
Bodies:CDSCOTakeda Pharmaceutical CompanyDr. Reddy's LaboratoriesIndian Council of Medical Research (ICMR)
Practice MCQs from today's news ▸
What This Article Covers

1.Qdenga is India's first approved dengue vaccine, authorised by CDSCO in July 2026 for individuals aged 4-60 years.

2.Dr. Reddy's Laboratories signed a distribution agreement with Takeda to promote and distribute the vaccine in India's private market, with availability expected in the first half of 2027.

3.The vaccine is a live-attenuated tetravalent vaccine (TAK-003) built on a DENV-2 backbone, administered as a two-dose regimen three months apart.

The Big Picture
Prelims · HighMains · Medium

India's first approved dengue vaccine, Qdenga (TAK-003), developed by Takeda, received CDSCO marketing authorisation in July 2026 for ages 4-60. Dr. Reddy's will promote and distribute it in the private market from the first half of 2027, while Takeda retains public market rights. This marks a critical step in addressing India's 11-fold rise in dengue cases over two decades.

Exam Lens

Quick Exam Facts From News

Vaccine NameQdenga (TAK-003)
Regulatory ApprovalCDSCO marketing authorisation in July 2026
Age Group4 to 60 years
Availability in IndiaFirst half of 2027 (private market)
ManufacturerTakeda Pharmaceutical Company
Distribution PartnerDr. Reddy's Laboratories (private market exclusive)
Dosage RegimenTwo doses, three months apart
Vaccine TypeLive-attenuated tetravalent dengue vaccine
Dengue Case Increase11-fold over past 20 years in India

1-Minute Revision

  • ›Vaccine Name: Qdenga (TAK-003)
  • ›Regulatory Approval: CDSCO marketing authorisation in July 2026
  • ›Target this Data: Qdenga (TAK-003) – India's first approved dengue vaccine; CDSCO approval July 2026; Age group 4-60 years; Two-dose regimen three months apart; Availability first half of 2027.
  • ›Target this Nodal Body: Central Drugs Standard Control Organisation (CDSCO) under Ministry of Health and Family Welfare.
  • ›Target this Legal Point: Marketing authorisation by CDSCO for a live-attenuated tetravalent dengue vaccine; Dr. Reddy's as exclusive private market distributor; Takeda retains public market rights.

Mastered this topic? Test your knowledge with a full MCQ quiz.

Practice exam-style questions, track your score, and strengthen your recall.

Q1Static LinkageEasy

Which regulatory body granted marketing authorisation to Qdenga, India's first approved dengue vaccine?

Q2Statement-basedHard

Consider the following statements regarding the Qdenga dengue vaccine:

1. Qdenga is a live-attenuated tetravalent vaccine built on a DENV-2 backbone.

2. Dr. Reddy's Laboratories will exclusively promote and distribute Qdenga in India's public market.

3. The vaccine is administered as a two-dose regimen given three months apart.

Which of the statements given above is/are correct?

Q3Data-centricMedium

According to the article, for which age group did CDSCO approve the Qdenga dengue vaccine?

Q4Application/ImpactMedium

What is the primary significance of the Qdenga vaccine approval for India's public health landscape?

All 20 MCQs ▸
You finished this topic
Explore Related Topics
Related Current Affairs
Science & Tech Current Affairs

CDSCO Approves Qdenga: India's First Dengue Vaccine to be Distributed by Dr Reddy's from 2027

India’s first approved dengue vaccine Qdenga will enter the private market in 2027 via Dr Reddy’s, after CDSCO approval in July 2026. The vaccine is effective against all four serotypes, requires no pre-vaccination screening, and shows 61.2% efficacy against dengue and 84.1% against hospitalization. This is a landmark step in India's fight against dengue.

Science & Tech Current Affairs

India Gets First Disease-Modifying Alzheimer's Drug Leqembi After CDSCO Nod

Eisai's Leqembi (lecanemab), India's first disease-modifying therapy for early Alzheimer's, has been launched after CDSCO approval. This marks a shift from symptomatic to disease-modifying treatment, but challenges of early diagnosis, biomarker infrastructure, and affordability remain significant.

Science & Tech Current Affairs

Merck-Moderna's Personalised mRNA Cancer Vaccine Intismeran Reduces Melanoma Death Risk by 49%

A first-of-its-kind personalised mRNA cancer vaccine (intismeran), developed by Merck and Moderna, combined with Keytruda, has shown a 49% reduction in risk of death from melanoma recurrence and 59% from spread in Phase 3 trials. This marks a breakthrough for cancer vaccines but has limited impact in India due to low melanoma incidence and high cost of immunotherapy.

Polity Current Affairs

MeitY Summons Meta Global Team Over Algorithmic Bias; Parliamentary Panel to Question

Government summons Meta's global team to clarify algorithmic bias and role in public order after MeitY rejects technical glitch explanation. Parliamentary panel will also question the company. This highlights growing regulatory scrutiny on social media algorithms and their societal impact.

Social Issues Current Affairs

NOTTO Reports 20,000+ Transplants in 2025, Launches Portal and Swap Guidelines

NOTTO released 2025 data showing over 20,000 transplants, persistent gender disparity in organ donation (68% female donors vs 78% male recipients), and launched a new digital portal to enhance transparency. New swap transplantation guidelines aim to expand matching beyond single hospitals, but legal recognition under THOTA is still pending.

Science & Tech Current Affairs

IARC Classifies Three WHO Essential Medicines as Group 1 Carcinogens: Hydrochlorothiazide, Voriconazole, Tacrolimus

IARC, the WHO cancer research agency, has classified three widely used drugs—hydrochlorothiazide, voriconazole, and tacrolimus—as Group 1 carcinogens. Despite this, experts stress that patients should not stop treatment as the benefits for hypertension, fungal infections, and organ transplant rejection far outweigh the cancer risk. The drugs are on the WHO Model List of Essential Medicines and are commonly prescribed in India.

Science & Tech Current Affairs

IISc SraVaani: India's First Open-Source Speech Recognition Model for 65 Languages

IISc's SPIRE Lab, in collaboration with ARTPARK and Google, has released SraVaani – the first multilingual Indian speech recognition model trained on 65 languages and dialects. It extends ASR to 45 underserved regional languages, potentially benefiting 25 crore people. This marks a major step in inclusive AI for India's linguistic diversity.

Social Issues Current Affairs

Meta Trial: $567 Mn Penalty for Child Addiction, 29-State Probe on Social Media Design

A US trial against Meta over addictive social media design for children could reshape Big Tech accountability. With penalties of $567 million and a $6 million jury verdict, this case highlights the growing scrutiny of platform design and its impact on youth mental health, a key issue for GS2 (Social Justice) and GS3 (Technology).

India to Launch First Approved…, Current Affairs for Exams